Disease Information

General Information of the Disease (ID: DIS00317)

Type(s) of Resistant Mechanism of This Disease

EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s)

1 drug(s) in total

Click to Show/Hide the Full List of Drugs

Artenimol

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Key Molecule: H19, imprinted maternally expressed transcript (H19)				[1]
Resistant Disease	Hepatic fibrosis [ICD-11: DB93.0]
Molecule Alteration	Up-regulation		Interaction	Molecule Info
Resistant Drug	Artenimol			Drug Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	HSC cells	N.A.	.	N.A.
Experiment for Molecule Alteration	Knockdown assay
Mechanism Description	LncRNA-H19 induces hepatic stellate cell activation via upregulating alcohol dehydrogenase III-mediated retinoic acid signals.

Investigative Drug(s)

2 drug(s) in total

Click to Show/Hide the Full List of Drugs

Carbon tetrachloride

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Key Molecule: Growth arrest specific 5 (GAS5)				[2]
Resistant Disease	Hepatic fibrosis [ICD-11: DB93.0]
Molecule Alteration	Down-regulation		Interaction	Molecule Info
Resistant Drug	Carbon tetrachloride			Drug Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	HSC cells	N.A.	.	N.A.
In Vivo Model	Rat hepatic fibrosis model			Rattus norvegicus
Experiment for Molecule Alteration	qRT-PCR; Western bloting analysis; Dual luciferase assay; RNA pull down assay
Mechanism Description	LncRNA GAS5/miR-23a may bring molecular targets for hepatic fibrosis therapy.LncRNA GAS5 restrains CCl4-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathway.

Lipopolysaccharide

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Key Molecule: Taurine up-regulated 1 (TUG1)				[3]
Resistant Disease	Hepatic cirrhosis [ICD-11: DB93.1]
Molecule Alteration	Up-regulation		Interaction	Molecule Info
Resistant Drug	Lipopolysaccharide			Drug Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	LSECs	Liver	Homo sapiens (Human)	CVCL_QY34
Experiment for Molecule Alteration	Knockdown assay; Overexpression assay; qRT-PCR; Western bloting analysis; Co-immunofluorescence staining; Immunohistochemical assay; RNA-seq; Luciferase assay; FISH assay; RIP experiments assay; ELISA assay
Experiment for Drug Resistance	WST assay; Flow cytometry assay; Transwell assay
Mechanism Description	TUG1 promotes LPS-induced autophagy and EndMT of LSECs by functioning as an endogenous sponge for miR-142-3p and promoting the expression of A TG5. LPS and miR-142-3p are potential diagnostic and therapeutic targets in cirrhosis.

References

Ref 1	Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axisAnticancer Drugs. 2020 Jun;31(5):473-482. doi: 10.1097/CAD.0000000000000888.
Ref 2	lncRNA GAS5 restrains CCl(4)-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathwayAm J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G539-G550. doi: 10.1152/ajpgi.00249.2018. Epub 2019 Feb 8.
Ref 3	Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibitionAging (Albany NY). 2019 Sep 18;11(18):7553-7569. doi: 10.18632/aging.102271. Epub 2019 Sep 18.